4D Molecular Therapeutics (NASDAQ:FDMT) Earns Underweight Rating from Analysts at Morgan Stanley

Research analysts at Morgan Stanley began coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) in a research report issued on Thursday,Briefing.com Automated Import reports. The brokerage set an "underweight" rating and a $8.00 price target on the stock. Morgan Stanley's price objective points to a potential downside of 4.88% from the company's previous close.

Other analysts have also issued research reports about the stock. Leerink Partners restated an "outperform" rating and set a $36.00 price target (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. HC Wainwright reissued a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Royal Bank of Canada dropped their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating on the stock in a research report on Thursday, November 14th. Chardan Capital reissued a "buy" rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Finally, Cantor Fitzgerald lowered 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $42.13.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock opened at $8.41 on Thursday. The stock has a market capitalization of $388.79 million, a PE ratio of -2.95 and a beta of 2.82. 4D Molecular Therapeutics has a 52 week low of $7.32 and a 52 week high of $36.25. The stock has a 50 day moving average price of $9.88 and a two-hundred day moving average price of $16.72.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. nVerses Capital LLC bought a new stake in shares of 4D Molecular Therapeutics during the third quarter valued at about $40,000. Values First Advisors Inc. bought a new position in shares of 4D Molecular Therapeutics in the third quarter worth $57,000. Quest Partners LLC raised its holdings in shares of 4D Molecular Therapeutics by 17,409.1% in the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company's stock valued at $121,000 after acquiring an additional 5,745 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of 4D Molecular Therapeutics by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock valued at $108,000 after acquiring an additional 3,922 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at about $108,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.